An exceptional opportunity has arisen to provide business and finance leadership within the purpose-built Medicines Manufacturing Centre (MMC). Based in Seaton Delaval, Northumberland, the MMC will produce sterile injectable medicinal products in line with MHRA Good Manufacturing Practice on behalf of the North East and North Cumbria Provider Collaborative. The post holder will act as the Finance and Business Manager.
The Finance and Business Manager will provide senior leadership, strategic management, and commercial acumen for the company as they evolve and go through a period from start-up to significant growth.
The post holder will drive the delivery of well-managed budgets and ensure the financial viability of the Company. Rigorous contract management, bona fide checks of customers and suppliers, robust delivery of agreed KPIs, and project management will also be a key feature of the role. The post holder will have direct accountability to the Board and will be required to attend meetings of the MMC Board of Directors, as well as leading the Finance and contracting group with representatives from all partners discussing delivery of SLAs for services delivered into and out of the organisation.
This role will sit on the senior management team, will provide line management duties to the purchasing and procurement team, and report into the Managing Director of the MMC. The post holder will influence and support the strategic vision and will be responsible for the development and delivery of strategic objectives, oversight of performance and risk, use of resources, and delivery of services to deliver high-quality products.
The MMC is in the late stages of design, with the facility build phase planned through to September 2025. This presents an exciting opportunity to be involved in the design and build of a new facility, the development of new production processes, and contribution to establishing a functional PQS for the facility.
Staff will be employed by Northumbria Healthcare Foundation NHS Trust until the formation of the Medicines Manufacturing Centre Legal Liability Partnership (LLP) is formed as a legal entity, after which TUPE regulations will apply.
Regionally circa 4 million injectable products are produced per annum. Projected to deliver in the region of 1.3 million products across chemotherapy, ready-to-administer antibiotics, and over-labelling by 2026. The aggregate 10-year revenue budget is expected to be circa £750 million. The MMC will employ circa 150 staff across various roles including: Production, Quality Assurance/Quality Control, and Warehousing, as well as Corporate/Support services including Purchasing, IT, HR, Training and Business Management.
For further details / informal visits contact: Name: Kyle Winn Job title: Head of Production Email address: kyle.winn1@nhs.net Telephone number: 07738421965
#J-18808-Ljbffr